Please use this identifier to cite or link to this item:
https://scholarhub.balamand.edu.lb/handle/uob/7139
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Chami, Perla | en_US |
dc.contributor.author | Diab, Youssef | en_US |
dc.contributor.author | Khalil, Danny N | en_US |
dc.contributor.author | Azhari, Hassan | en_US |
dc.contributor.author | Jarnagin, William R | en_US |
dc.contributor.author | Abou-Alfa, Ghassan K | en_US |
dc.contributor.author | Harding, James J | en_US |
dc.contributor.author | Hajj, Joseph | en_US |
dc.contributor.author | Ma, Jennifer | en_US |
dc.contributor.author | El Homsi, Maria | en_US |
dc.contributor.author | Reyngold, Marsha | en_US |
dc.contributor.author | Crane, Christopher | en_US |
dc.contributor.author | Hajj, Carla | en_US |
dc.date.accessioned | 2023-12-20T09:27:39Z | - |
dc.date.available | 2023-12-20T09:27:39Z | - |
dc.date.issued | 2023-11-26 | - |
dc.identifier.issn | 16616596 | - |
dc.identifier.uri | https://scholarhub.balamand.edu.lb/handle/uob/7139 | - |
dc.description.abstract | The liver tumor immune microenvironment has been thought to possess a critical role in the development and progression of hepatocellular carcinoma (HCC). Despite the approval of immune checkpoint inhibitors (ICIs), such as programmed cell death receptor 1 (PD-1)/programmed cell death ligand 1 (PD-L1) and cytotoxic T lymphocyte associated protein 4 (CTLA-4) inhibitors, for several types of cancers, including HCC, liver metastases have shown evidence of resistance or poor response to immunotherapies. Radiation therapy (RT) has displayed evidence of immunosuppressive effects through the upregulation of immune checkpoint molecules post-treatment. However, it was revealed that the limitations of ICIs can be overcome through the use of RT, as it can reshape the liver immune microenvironment. Moreover, ICIs are able to overcome the RT-induced inhibitory signals, effectively restoring anti-tumor activity. Owing to the synergetic effect believed to arise from the combination of ICIs with RT, several clinical trials are currently ongoing to assess the efficacy and safety of this treatment for patients with HCC. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | National Library of Medicine | en_US |
dc.subject | Combination therapy | en_US |
dc.subject | Hepatocellular carcinoma | en_US |
dc.subject | Immune checkpoint inhibitors | en_US |
dc.subject | Immunotherapy | en_US |
dc.subject | Radiation therapy | en_US |
dc.title | Radiation and Immune Checkpoint Inhibitors: Combination Therapy for Treatment of Hepatocellular Carcinoma | en_US |
dc.type | Journal Article | en_US |
dc.identifier.doi | 10.3390/ijms242316773 | - |
dc.identifier.pmid | 38069095 | - |
dc.identifier.scopus | 2-s2.0-85179300496 | - |
dc.identifier.url | https://api.elsevier.com/content/abstract/scopus_id/85179300496 | - |
dc.contributor.affiliation | Faculty of Medicine | en_US |
dc.contributor.affiliation | Faculty of Medicine | en_US |
dc.description.volume | 24 | en_US |
dc.description.issue | 23 | en_US |
dc.date.catalogued | 2023-12-20 | - |
dc.description.status | Published | en_US |
dc.identifier.openURL | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10706661/ | en_US |
dc.relation.ispartoftext | International Journal of Molecular Sciences | en_US |
Appears in Collections: | Faculty of Medicine |
SCOPUSTM
Citations
2
checked on Sep 7, 2024
Record view(s)
49
checked on Sep 7, 2024
Google ScholarTM
Check
Altmetric
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.